Clinical trials: Individual Psychiatric Disorder
Schizophrenia
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05628103
- Testing
- SEP-363856
- Where
- 25 sites in United States
- Volunteers
- 101 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Idiopathic Hypersomnia, Narcolepsy Type 1
A Study of TAK-360 in People With Narcolepsy or Idiopathic Hypersomnia
Central hypersomnia conditions are a group of sleeping disorders where the brain has trouble keeping a person awake during the day (called excessive daytime sleepiness or EDS).
- Conditions
- Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
- Trial name
- NCT07646678
- Testing
- TAK-360
- Where
- 31 sites in United States, Australia and 3 more
- Volunteers
- 500 people
- Sponsor
- Takeda
Posttraumatic Stress Disorder
MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder
The goal of this clinical trial is to compare MDMA-assisted therapy to placebo with therapy in people with chronic, treatment-resistant posttraumatic stress disorder (PTSD).
- Trial name
- NCT00090064
- Testing
- Midomafetamine HCl, Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Resilient Pharmaceuticals
Schizophrenia
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
A clinical trial study to determine the effect of an investigational drug (SEP-363856) has on the way that the drug Metformin travels through the body in people with schizophrenia.
- Trial name
- NCT04865835
- Testing
- SEP-363856, metformin
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer Disease
A Phase I Study of DDN-A-0101 in Healthy Volunteers and Elder People
The study is a Phase I, randomized double-blind, placebo-controlled, single and multiple dosing, dose-escalation study of the oral administration of DDN-A-0101 in healthy adults and elderly subjects
- Trial name
- NCT06367426
- Testing
- DDN-A-0101 (SAD), DDN-A-0101 (MAD)
- Where
- South Korea
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pharmacobio
Narcolepsy
A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the…
- Trial name
- NCT04803786
- Testing
- Transition from Xyrem to Xywav
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Jazz Pharmaceuticals
Bipolar Disorder (BD), Schizophrenia Disorders
Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness
This observational study aims to provide new insights into the nature and classification of severe mental illness and dementias that in time should help improve diagnostic practise, and enable the development of new and improved…
- Conditions
- Bipolar Disorder (BD), Schizophrenia Disorders, Major Depressive Diorder, Dementia
- Trial name
- GlobalMinds (NCT06641726)
- Testing
- Not applicable- observational study
- Where
- United Kingdom
- Volunteers
- 50,000 people
- Sponsor
- Akrivia Health
Depressive Disorder, Major
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
This is a home-based study in adults with depression. People who have been diagnosed with Major Depressive Disorder can participate in the study.
- Trial name
- NCT04423757
- Testing
- BI 1358894
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Generalized Anxiety Disorder (GAD), Major Depressive Disorder (MDD)
AI-Supported Therapy for Depression and Anxiety Compared With Standard CBT
This study is a pivotal, randomised, controlled, non-inferiority trial evaluating "Nook," an AI-delivered, neurosymbolic, clinician-supervised digital psychological intervention for depression and anxiety, compared with standard…
- Trial name
- NCT07620340
- Testing
- AI-Digital CBT, Cognitive Behavioural Therapy
- Volunteers
- 400 people
- Sponsor
- PsyScale